BioMarin Pharmaceuticalvs.Gilead Sciences
BMRN vs GILD · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Gilead Sciences is about 14× larger than BioMarin Pharmaceutical by market cap; Gilead Sciences trades at the lower P/E (17.5 vs 42.6); year to date, Gilead Sciences leads (+5.8% vs −0.5%).
Side by side
| BMRN | GILD | |
|---|---|---|
| Market cap | $11.4B | $162B |
| Price | $59.12 | $129.83 |
| Today | −1.4% | −3.7% |
| Return YTD | −0.5% | +5.8% |
| Return 1Y | +0.5% | +13.3% |
| P/E | 42.6 | 17.5 |
| P/S | 3.5 | 5.4 |
| P/B | 1.8 | 6.9 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
BioMarin PharmaceuticalBMRN
Biopharma specialized in enzyme and gene therapies for rare genetic diseases.
Full BMRN profile →Gilead SciencesGILD
American biotech company and global leader in HIV treatment, with a growing oncology portfolio.
Full GILD profile →More comparisons in Biotech & innovation
See where BMRN and GILD sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →